Over 1 Year Ago
1 Min Read
Off goes COGT. The stock gained today. The primary reasons:
Cogent Biosciences Inc (COGT) is trading 11% higher at $15.77 today. Shares of the stock are zooming past other names in the space on what is turning out to be a mildly somber day for the Health Care sector.
A strong factor in the price movement would likely be the most recent earnings call on August 15. Despite reporting an earnings miss trader seem to be gobbling up shares of the biotech as it trades near 52 week highs.
Cogent Biosciences Inc has been trading between a 52-week high of $14.85 and a 52-week low of $3.79. The stock has a market cap of $1.04 Billion.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, PLX9486, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells.
A strong factor in the price movement would likely be the most recent earnings call on August 15. Despite reporting an earnings miss trader seem to be gobbling up shares of the biotech as it trades near 52 week highs.
Cogent Biosciences Inc has been trading between a 52-week high of $14.85 and a 52-week low of $3.79. The stock has a market cap of $1.04 Billion.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, PLX9486, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells.
Recommended Articles
